Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional Results available

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy

ClinicalTrials.gov ID: NCT03755791

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03755791. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 12:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy. A single-agent cabozantinib arm will be enrolled in which participants receive single agent cabozantinib in order to determine its contribution to the overall safety and efficacy of the combination with atezolizumab.

Study identification

NCT ID
NCT03755791
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Exelixis
Industry
Enrollment
837 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 10, 2018 (Actual)
Primary completion
Nov 30, 2021 (Actual)
Completion
Jul 31, 2026 (Estimated)
Last update posted
Dec 11, 2025

2018 – 2026

United States locations

U.S. sites
33
U.S. states
19
U.S. cities
29
Facility City State ZIP Site status
Exelixis Clinical Site #208 Phoenix Arizona 85004 —
Exelixis Clinical Site #159 Tucson Arizona 85719 —
Exelixis Clinical Site #44 La Jolla California 92037 —
Exelixis Clinical Site #112 Los Angeles California 90033 —
Exelixis Clinical Site #200 Orange California 92868-3201 —
Exelixis Clinical Site #2 Rialto California 92377 —
Exelixis Clinical Site #207 San Diego California 92093 —
Exelixis Clinical Site #109 San Francisco California 94115 —
Exelixis Clinical Site #54 San Francisco California 94158 —
Exelixis Clinical Site #58 Washington D.C. District of Columbia 20007 —
Exelixis Clinical Site #191 Miami Florida 33125 —
Exelixis Clinical Site #4 Atlanta Georgia 30318 —
Exelixis Clinical Site #195 Chicago Illinois 60612 —
Exelixis Clinical Site #120 Chicago Illinois 60637 —
Exelixis Clinical Site #6 Baltimore Maryland 21202 —
Exelixis Clinical Site #7 Burlington Massachusetts 01805 —
Exelixis Clinical Site #11 Kansas City Missouri 64128 —
Exelixis Clinical Site #5 Kansas City Missouri 64131 —
Exelixis Clinical Site #8 St Louis Missouri 63110 —
Exelixis Clinical Site #1 Las Vegas Nevada 89169 —
Exelixis Clinical Site #14 New Brunswick New Jersey 08903 —
Exelixis Clinical Site #76 Albuquerque New Mexico 87131 —
Exelixis Clinical Site #12 Chapel Hill North Carolina 27599-7600 —
Exelixis Clinical Site #39 Toledo Ohio 43614 —
Exelixis Clinical Site #176 Portland Oregon 97213 —
Exelixis Clinical Site #88 Philadelphia Pennsylvania 19107 —
Exelixis Clinical Site #144 Charleston South Carolina 29425 —
Exelixis Clinical Site #199 Dallas Texas 75246 —
Exelixis Clinical Site #154 Houston Texas 77030 —
Exelixis Clinical Site #19 Temple Texas 76508 —
Exelixis Clinical Site #13 Seattle Washington 98101 —
Exelixis Clinical Site #46 Seattle Washington 98109 —
Exelixis Clinical Site #3 Spokane Washington 99208 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 212 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03755791, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 11, 2025 · Synced Nov 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.